Amidst concerns about global growth and a stronger euro, the pan-European STOXX Europe 600 Index recently ended slightly lower, reflecting mixed performances across major European stock indexes. In such a market landscape, investors often seek opportunities that balance potential with financial resilience. Penny stocksβ€”often representing smaller or newer companiesβ€”remain relevant for those willing to explore beyond established names, offering unique growth possibilities when backed by solid financials.

Name

Share Price

Market Cap

Financial Health Rating

Ariston Holding (BIT:ARIS)

€4.26

€1.47B

β˜…β˜…β˜…β˜…β˜…β˜†

Maps (BIT:MAPS)

€3.37

€44.76M

β˜…β˜…β˜…β˜…β˜…β˜…

Angler Gaming (NGM:ANGL)

SEK3.60

SEK269.95M

β˜…β˜…β˜…β˜…β˜…β˜…

Angler Gaming (DB:0QM)

€0.37

€247.45M

β˜…β˜…β˜…β˜…β˜…β˜…

Cellularline (BIT:CELL)

€3.14

€66.23M

β˜…β˜…β˜…β˜…β˜…β˜†

Euroland SociΓ©tΓ© anonyme (ENXTPA:ALERO)

€3.20

€10.15M

β˜…β˜…β˜…β˜…β˜…β˜…

ForFarmers (ENXTAM:FFARM)

€4.475

€395.52M

β˜…β˜…β˜…β˜…β˜…β˜…

High (ENXTPA:HCO)

€3.69

€72.54M

β˜…β˜…β˜…β˜…β˜…β˜…

Deceuninck (ENXTBR:DECB)

€2.11

€291.65M

β˜…β˜…β˜…β˜…β˜…β˜…

Netgem (ENXTPA:ALNTG)

€0.93

€31.36M

β˜…β˜…β˜…β˜…β˜…β˜…

Click here to see the full list of 330 stocks from our European Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Financial Health Rating: β˜…β˜…β˜…β˜…β˜†β˜†

Overview: Cellectis S.A. is a clinical stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €175.03 million.

Operations: The company’s revenue is derived entirely from its therapeutics segment, amounting to $63.44 million.

Market Cap: €175.03M

Cellectis S.A., a clinical-stage biotech firm, has shown significant revenue growth with US$18.19 million in Q2 2025 compared to US$9.5 million the previous year, though it remains unprofitable with a net loss of US$23.74 million for the quarter. Despite high volatility and negative return on equity, the company trades at a good value relative to peers and maintains more cash than debt, providing some financial stability. Recent strategic engagements at major healthcare conferences underscore its commitment to advancing its gene-editing technologies amid ongoing financial challenges and limited cash runway of less than one year if current trends persist.

ENXTPA:ALCLS Debt to Equity History and Analysis as at Sep 2025

ENXTPA:ALCLS Debt to Equity History and Analysis as at Sep 2025

Simply Wall St Financial Health Rating: β˜…β˜…β˜…β˜…β˜†β˜†

Story Continues